First CAR T-Cell Therapy Approved for Solid Tumors.

China approves satricabtagene autoleucel, the first CAR T-cell therapy for solid tumors, showing promise in gastric and gastro-esophageal cancers with improved survival metrics.

• Why it matters: This breakthrough addresses the challenge of developing effective immunotherapies for solid tumors, a field where success has been limited compared to blood cancers.
• What they did: A phase II trial involving satricabtagene autoleucel demonstrated increased progression-free and overall survival in patients with claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer.
• The result: The approval paves the way for further research to enhance CAR T-cell efficacy against solid tumors, potentially expanding treatment options for these cancers.